Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. XNCR
XNCR logo

XNCR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Xencor Inc (XNCR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
11.890
1 Day change
4.21%
52 Week Range
18.690
Analysis Updated At
2026/06/05
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

XNCR is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some near-term technical improvement, but the broader trend is still mixed to bearish, analyst sentiment remains Neutral, and there is no strong proprietary buy signal. I would not call it a clear buy at current levels; the better stance is hold and wait for stronger catalyst confirmation.

Technical Analysis

Current price is 11.84, down 1.42% on the day and also weaker in pre-market. The MACD histogram is positive and expanding, which supports short-term momentum improvement, but RSI_6 at 55.57 is only neutral. The bigger issue is the moving average structure: SMA_200 > SMA_20 > SMA_5, which is a bearish alignment and suggests the stock is still trading below a stronger long-term trend. Key levels are Pivot 11.659, support at 11.222 and 10.951, with resistance at 12.096 and 12.367. The stock appears range-bound rather than in a confirmed uptrend.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is mildly cautious. The put-call open interest ratio of 1.14 suggests slightly more bearish positioning than bullish. However, today’s option volume put-call ratio is 0.0, which indicates very little downside hedging or active directional flow today. Implied volatility is extremely elevated at 493.58 with IV percentile at 100, showing the market expects major movement or event risk, but there is no clear bullish options confirmation.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
10

Positive Catalysts

    • AI Stock Picker: No signal on given stock today.
    • SwingMax: No signal on given stock recently.
    • JPMorgan raised the target to $14 from $13 on 2026-05-11, showing slightly improved valuation confidence.
    • Positive MACD momentum suggests the stock may be stabilizing near current levels.
    • Incyte’s Monjuvi first-line survival news is a sector-related oncology headline that may support broader sentiment around cancer-drug development companies.

Neutral/Negative Catalysts

    • No insider buying, no notable hedge fund accumulation, and no congress trading activity were reported.

Financial Performance

No usable latest-quarter financial snapshot was provided because the financial data section returned an error. As a result, I cannot confirm revenue or earnings growth for the latest quarter season from the supplied data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is Neutral. JPMorgan downgraded XNCR on 2026-03-24 from Overweight to Neutral and reduced the target from $18 to $13, citing 2026 as an execution year and limited visibility on meaningful catalysts. On 2026-05-11, JPMorgan modestly lifted the target to $14 from $13 but kept Neutral, which is a slight improvement but still not a bullish stance. Overall Wall Street pros appear divided but cautious: the bull case is pipeline optionality and a slightly higher target, while the bear case is lack of clear differentiation, execution risk, and a range-bound setup.

Wall Street analysts forecast XNCR stock price to rise
5 Analyst Rating
Wall Street analysts forecast XNCR stock price to rise
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 11.410
sliders
Low
20
Averages
26.25
High
30
Current: 11.410
sliders
Low
20
Averages
26.25
High
30
JPMorgan
Neutral
maintain
$13 -> $14
AI Analysis
2026-05-11
Reason
JPMorgan
Price Target
$13 -> $14
AI Analysis
2026-05-11
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Xencor to $14 from $13 and keeps a Neutral rating on the shares.
JPMorgan
Overweight -> Neutral
downgrade
$18 -> $13
2026-03-24
Reason
JPMorgan
Price Target
$18 -> $13
2026-03-24
downgrade
Overweight -> Neutral
Reason
JPMorgan downgraded Xencor to Neutral from Overweight with a price target of $13, down from $18. The firm views the company's 2026 as an "execution year." Xencor's pipeline will need time to develop, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for XNCR
Unlock Now

People Also Watch